PHATHOM PHARMACEUTICALS, INC. Fair Value Adjustment of Warrants
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Fair Value Adjustment of Warrants of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-03-01
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2021-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2021-03-31 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for fiscal 2020 was -$95.00K, a 100.10% decline from fiscal 2019.
- PHATHOM PHARMACEUTICALS, INC. fair value adjustment of warrants for fiscal 2019 was $96.27M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | -$95.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | -$95.00K 10-Q · filed 2021-11-08 | $37.12M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$95.00K 10-Q · filed 2021-08-10 | $37.12M derived: sum of 3 quarters · filed 2021-08-10 | $94.89M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$95.00K 10-Q · filed 2021-05-11 | $37.12M derived: sum of 2 quarters · filed 2021-05-11 | $94.89M derived: sum of 3 quarters · filed 2021-05-11 | $96.18M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $37.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $94.99M derived: sum of 2 quarters · filed 2021-03-30 | $96.27M derived: sum of 3 quarters · filed 2021-03-30 | $96.27M 10-K · filed 2021-03-30 |
| 2019-09-30 | $57.78M 10-Q · filed 2020-11-10 | $59.06M derived: sum of 2 quarters · filed 2020-11-10 | $59.06M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $1.28M 10-Q · filed 2020-08-06 | $1.28M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |